nach oben

Erschienen in:

01.05.2017 | Review Article

LincRNa-p21: function and mechanism in cancer

verfasst von: Shaoyun Chen, Hairong Liang, Hui Yang, Kairu Zhou, Longmei Xu, Jiaxian Liu, Bei Lai, Li Song, Hao Luo, Jianming Peng, Zhidong Liu, Yongmei Xiao, Wen Chen, Huanwen Tang

Erschienen in: Medical Oncology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

In view of the rapid development of gene chips and high-throughput sequencing technology, noncoding RNAs (ncRNas) form a high percentage of the mammalian genome. Two major subgroups of ncRNAs that have been identified are the long ncRNAs (lncRNas) and the microRNAs. A number of studies in the past few years have showed crucial functions for lncRNas in cancer. LincRNa-p21 as a p53-dependent transcriptional target gene and a potential diagnostic marker is involved in proliferation, cell cycle, metabolism and reprogramming. In addition, more researches revealed that lincRNa-p21 is associated with cancer progression and contributed to the treatment and prognosis of cancer. In this review, we briefly summarize the function and molecular mechanisms of lincRNa-p21 in cancer and its regulation for the genes expression .

Gao D, Xiao Z, Li HP, Han DH, Zhang YP. LncRNA MALAT-1 elevates HMGB1 to promote autophagy resulting in inhibition of tumor cell apoptosis in multiple Myeloma. J Cell Biochem. 2017. doi:10.1002/jcb.25987.

Singh KK, Matkar PN, Pan Y, Quan A, Gupta V, Teoh H, et al. Endothelial long non-coding RNAs regulated by oxidized LDL. Mol Cell Biochem. 2017. doi:10.1007/s11010-017-2984-2.

Tang J, Xie Y, Xu X, Yin Y, Jiang R, Deng L, et al. Bidirectional transcription of Linc00441 and RB1 via H3K27 modification-dependent way promotes hepatocellular carcinoma. Cell Death Dis. 2017;8(3):e2675.PubMedCrossRef

Zhai H, Fesler A, Schee K, Fodstad Ø, Flatmark K, Ju J. Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer. Clin Colorectal Cancer. 2013;12(4):261–6.PubMedCrossRef

Huarte M, Guttman M, Feldser D, Garber M, Koziol MJ, Kenzelmann-Broz D, et al. A large intergenic noncoding rna induced by p53 mediates global gene repression in the p53 response. Cell. 2010;142(3):409–19.PubMedPubMedCentralCrossRef

Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7–21.PubMedCrossRef

Yoon JH, Abdelmohsen K, Srikantan S, Yang X, Martindale J, De S, et al. LincRNA-p21 suppresses target mRNA translation. Mol Cell. 2012;47(4):648–55.PubMedPubMedCentralCrossRef

Dimitrova N, Zamudio J, Jong R, Soukup D, Resnick R, Sarma K, et al. LincRNA-p21 activates p21 In cis to promote polycomb target gene expression and to enforce the G1/S checkpoint. Mol Cell. 2014;54(5):777–90.PubMedPubMedCentralCrossRef

Wu G, Cai J, Han Y, Chen J, Huang ZP, Chen C, et al. LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity. Circulation. 2014;130(17):1452–65.PubMedPubMedCentralCrossRef

10.

Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993;362(6423):857–60.PubMedCrossRef

11.

Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387(6630):296–9.PubMedCrossRef

12.

Yin Y, Stephen CW, Luciani MG, Fåhraeus R. p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol. 2002;4(6):462–7.PubMedCrossRef

13.

Wei G, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 1997;90(4):595–606.CrossRef

14.

Lin Liu DMSR. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol. 1999;19(2):1202–9.CrossRef

15.

Tang SS, Zheng BY, Xiong XD. LincRNA-p21: implications in human diseases. Int J Mol Sci. 2015;16(8):18732–40.PubMedPubMedCentralCrossRef

16.

Toyama T, Iwase H, Watson P, Muzik H, Saettler E, Magliocco A, et al. Suppression of ING1 expression in sporadic breast cancer. Oncogene. 1999;18(37):5187–93.PubMedCrossRef

17.

He GH, Helbing CC, Wagner MJ, Sensen CW, Riabowol K. Phylogenetic analysis of the ING family of PHD finger proteins. Mol Biol Evol. 1951;23(22):104–16.

18.

Gunduz M, Demircan K, Gunduz E, Katase N, Tamamura R, Nagatsuka H. Potential usage of ING family members in cancer diagnostics and molecular therapy. Curr Drug Targets. 2009;10(5):465–76.PubMedCrossRef

19.

Tran UM, Rajarajacholan U, Soh J, Kim T, Thalappilly S, Sensen CW, et al. LincRNA-p21 acts as a mediator of ING1b-induced apoptosis. Cell Death Disease. 2015;6(3):478.CrossRef

20.

Zheng J, Dong P, Mao Y, Chen S, Wu X, Li G, et al. LincRNA-p21 inhibits hepatic stellate cells activation and liver fibrogenesis via p21. FEBS J. 2015;282(24):4810–21.PubMedCrossRef

21.

Braun AC. On the origin of the cancer cells. Am Sci. 1970;58(3):307–20.PubMed

22.

Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004;5(5):343–54.PubMedCrossRef

23.

Kaelin WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30(4):393–402.PubMedCrossRef

24.

Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIF targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464–8.PubMedCrossRef

25.

Yang F, Zhang H, Mei Y, Wu M. Reciprocal regulation of HIF-1α and LincRNA-p21 modulates the Warburg effect. Mol Cell. 2013;53(1):88–100.PubMedCrossRef

26.

Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–76.PubMedCrossRef

27.

Polo J, Anderssen E, Walsh R, Schwarz B, Nefzger C, Lim SM, et al. A molecular roadmap of reprogramming somatic cells into iPS cells. Cell. 2012;151(7):1617–32.PubMedPubMedCentralCrossRef

28.

Liu L, Xu Y, He M, Zhang M, Cui F, Lu L, et al. Transcriptional pause release is a rate-limiting step for somatic cell reprogramming. Cell Stem Cell. 2014;15(5):2335–43.CrossRef

29.

Rais Y, Zviran A, Geula S, Gafni O, Chomsky E, Viukov S, et al. Corrigendum: deterministic direct reprogramming of somatic cells to pluripotency. Nature. 2013;502(7469):65–70.PubMedCrossRef

30.

Takahashi K, Yamanaka S. Induced pluripotent stem cells in medicine and biology. Development. 2013;140(12):2457–61.PubMedCrossRef

31.

Loewer S, Cabili MN, Guttman M, Loh YH, Thomas K, Park IH, et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 2010;42(12):1113–7.PubMedPubMedCentralCrossRef

32.

Lin N, Chang KY, Li Z, Gates K, Rana Z, Dang J, et al. An evolutionarily conserved long noncoding RNA TUNA controls pluripotency and neural lineage commitment. Mol Cell. 2014;53(6):1005–19.PubMedPubMedCentralCrossRef

33.

Bao X, Wu H, Zhu X, Guo X, Hutchins AP, Luo Z, et al. The p53-induced lincRNA-p21 derails somatic cell reprogramming by sustaining H3K9me3 and CpG methylation at pluripotency gene promoters. Cell Res. 2014;25(1):80–92.PubMedPubMedCentralCrossRef

34.

Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci Robbins ES, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol. 1998;141(7):1659–73.PubMedPubMedCentralCrossRef

35.

Spurlock CF, Tossberg JT, Matlock BK, Olsen NJ, Aune TM. Methotrexate inhibits NF-κB activity via long intergenic (noncoding) RNA-p21 induction. Arthritis Rheumatol. 2014;66(11):2947–57.PubMedPubMedCentralCrossRef

36.

Yang N, Fu Y, Zhang H, Hui S, Zhu N, Yang G. LincRNA-p21 activates endoplasmic reticulum stress and inhibits hepatocellular carcinoma. Oncotarget. 2015;6(29):28151–63.PubMedCrossRef

37.

Işın M, Uysaler E, Özgür E, Yücel ÖB, Gezer U, Dalay N. Exosomal lncRNA-p21 levels may help to distinguish prostate cancer from benign disease. Front Genet. 2015;6:168.PubMedPubMedCentral

38.

Pihikova D, Kasak P, Kubanikova P, Sokol R, Tkac J. Aberrant sialylation of a prostate-specific antigen: electrochemical label-free glycoprofiling in prostate cancer serum samples. Anal Chim Acta. 2016;934:72–9.PubMedCrossRef

39.

Zengle G, Xu B, Chen M. Long chain non-coding RNA in the progress of prostate cancer. J Southeast Univ (Med Sci Ed). 2016;35(3):431–6.

40.

Wang R, Zhang X, Wang C-X. Research advance on long non-coding RNA in cancer. J Pract Hosp. 2016;13(3):9–13.

41.

Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012;9(6):703–19.PubMedPubMedCentralCrossRef

42.

Castellazzi M, Spyrou G, La VN, Dangy JP, Piu F, Yaniv M, et al. Overexpression of c-jun, junB, or junD affects cell growth differently. Proc Natl Acad Sci USA. 1991;88(20):8890–4.PubMedPubMedCentralCrossRef

43.

Dong Z, Watts R, Sun Y, Zhan S, Colburn N. Progressive elevation of ap-1 activity during preneoplastic-to-neoplastic progression as modeled in mouse jb6 cell variants. Int J Oncol. 1995;7(2):359–64.PubMed

44.

Wang G, Li Z, Zhao Q, Zhu Y, Zhao C, Li X, et al. LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/β-catenin signaling pathway. Oncol Rep. 2014;31(4):1839–45.PubMed

45.

White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology. 2012;142(2):219–32.PubMedCrossRef

46.

Kendziorra E, Ahlborn K, Spitzner M, Emons G, Gaedcke J, Kramer F, et al. Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. Carcinogenesis. 2011;32(12):1824–31.PubMedPubMedCentralCrossRef

47.

Waaler J, Machon O, von Kries JP, Wilson SR, Lundenes E, Wedlich D, et al. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Can Res. 2011;71(1):197–205.CrossRef

48.

Michael B. Crosstalk between Wnt signaling and RNA processing in colorectal cancer. J Cancer. 2013;4(2):96–103.CrossRef

49.

Castellano JJ, Navarro A, Vinolas N, Marrades RM, Moises J, Cordeiro A, et al. LincRNA-p21 impacts prognosis in resected non-small-cell lung cancer patients through angiogenesis regulation. J Thorac Oncol. 2016;11(12):2173–82.PubMedCrossRef

50.

Battegay EJ. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF & #946;-receptors. J Cell Biol. 1994;125(4):917–28.PubMedCrossRef

51.

Rojiani MV, Alidina J, Esposito N, Rojiani AM. Expression of MMP-2 correlates with increased angiogenesis in CNS metastasis of lung carcinoma. Int J Clin Exp Pathol. 2010;3(8):775–81.PubMedPubMedCentral

52.

de Mello RA, Costa BM, Reis RM, Hespanhol V. Insights into angiogenesis in non-small cell lung cancer: molecular mechanisms, polymorphic genes, and targeted therapies. Recent patents on anti-cancer drug discovery. 2012;7(1):118–31(14).

53.

Toh H, Cao M, Daniels E, Bateman A. Expression of the growth factor progranulin in endothelial cells influences growth and development of blood vessels: a novel mouse model. PLoS ONE. 2013;8(5):e64989.PubMedPubMedCentralCrossRef

54.

Beckham CJ, Olsen J, Yin PN, Wu CH, Ting HJ, Hagen FK, et al. Bladder cancer exosomes contain EDIL-3/Del1 and facilitate cancer progression. J Urol. 2014;192(2):583–92.PubMedCrossRef

55.

Yang F, Zhang H, Mei Y, Wu M. Reciprocal regulation of HIF-1α and LincRNA-p21 modulates the Warburg effect. Mol Cell. 2014;53(1):88–100.PubMedCrossRef

56.

Blume CJ, Hotz-Wagenblatt A, Hullein J, Sellner L, Jethwa A, Stolz T, et al. p53-dependent non-coding RNA networks in chronic lymphocytic leukemia. Leukemia. 2015;29(10):2015–23.PubMedCrossRef

57.

Jiang YJ, Bikle DD. LncRNA profiling reveals new mechanism for VDR protection against skin cancer formation. J Steroid Biochem Mol Biol. 2014;144(part A):87–90.PubMed

58.

Hall JR, Messenger ZJ, Tam HW, Phillips SL, Recio L, Smart RC. Long noncoding RNA lincRNA-p21 is the major mediator of UVB-induced and p53-dependent apoptosis in keratinocytes. Cell Death Disease. 2015;6(3):e1700.PubMedPubMedCentralCrossRef

Titel: LincRNa-p21: function and mechanism in cancer
verfasst von: Shaoyun Chen
Hairong Liang
Hui Yang
Kairu Zhou
Longmei Xu
Jiaxian Liu
Bei Lai
Li Song
Hao Luo
Jianming Peng
Zhidong Liu
Yongmei Xiao
Wen Chen
Huanwen Tang
Publikationsdatum: 01.05.2017
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 5/2017
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-017-0959-5

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

LincRNa-p21: function and mechanism in cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2017

Erratum to: Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization

Molecular profiling of gene copy number abnormalities in key regulatory genes in high-risk B-lineage acute lymphoblastic leukemia: frequency and their association with clinicopathological findings in Indian patients

Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms

Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo

ALK rearrangement in specific subtypes of lung adenocarcinoma: immunophenotypic and morphological features

Microwave ablation of malignant renal tumours: intermediate-term results and usefulness of RENAL and mRENAL scores for predicting outcomes and complications

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie